# Study of E7389 Administered Once Every 3 Weeks In Patients With Advanced Solid Tumors

> **NCT00069277** · PHASE1 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 21 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** E7389

## Key facts

- **NCT ID:** NCT00069277
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-08
- **Primary completion:** 2005-04
- **Final completion:** 2005-04
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2012-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00069277

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00069277, "Study of E7389 Administered Once Every 3 Weeks In Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00069277. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*